[Organ-confined prostate cancer: treatment with high doses of radioterapy (intensity modulated radiotherapy)]
- PMID: 17896557
- DOI: 10.1016/s0210-4806(07)73697-5
[Organ-confined prostate cancer: treatment with high doses of radioterapy (intensity modulated radiotherapy)]
Abstract
Purpose: To report toxicity and local control in patients with localized prostate cancer, treated with high dose radiotherapy.
Materials and methods: The records of 100 consecutive patients with clinically localized prostate cancer treated between june 2003 and may 2006 were reviewed. They received 80 Gy to the target volume with a biphasic technique (3DCRT + IMRT). The median pretreatment PSA was 9. The median follow-up time was 12 months.
Results: Eighteen (18%) developed acute Grade 2 rectal toxicity, and no patient experienced acute grade 3 or higher rectal symptoms. Forty-four (44%) developed acute Grade 2 urinary symptoms while 34% of the patients experienced no GU symptoms (Grade 0) during treatment. Three patients (3%) developed late rectal toxicity grade 2 and eight patients (8%) experienced late urinary toxicity grade 2; any patients experienced more severe symptoms. We recorded biochemical relapse in two patients, both had poor prognostic factors at initial diagnosis of prostate cancer.
Conclusions: The data demonstrate the feasibility and safety of high dose radiotherapy for patients with localized prostate cancer and provide a proof that this method allow safe dose escalation with low severe toxicities to the normal tissues.
Similar articles
-
Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058. Epub 2010 Dec 14. Int J Radiat Oncol Biol Phys. 2012. PMID: 21163587
-
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044. Int J Radiat Oncol Biol Phys. 2008. PMID: 18313526
-
Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.Radiat Oncol. 2017 Jun 16;12(1):99. doi: 10.1186/s13014-017-0839-3. Radiat Oncol. 2017. PMID: 28622770 Free PMC article.
-
Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):777-87. doi: 10.1016/j.ijrobp.2004.04.017. Int J Radiat Oncol Biol Phys. 2004. PMID: 15465194 Review.
-
[Benefit of intensity modulated and image-guided radiotherapy in prostate cancer].Cancer Radiother. 2010 Oct;14(6-7):479-87. doi: 10.1016/j.canrad.2010.06.013. Epub 2010 Aug 24. Cancer Radiother. 2010. PMID: 20797889 Review. French.
Cited by
-
Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma.Radiat Oncol. 2013 Apr 8;8:82. doi: 10.1186/1748-717X-8-82. Radiat Oncol. 2013. PMID: 23566526 Free PMC article. Clinical Trial.
-
The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures.PLoS One. 2016 May 12;11(5):e0154499. doi: 10.1371/journal.pone.0154499. eCollection 2016. PLoS One. 2016. PMID: 27171271 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous